Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene expression profiling may lead to customized treatments for pediatric leukemia patients

06.10.2003


Gene expression profiling can help doctors accurately identify subtypes of pediatric acute lymphoblastic leukemia (ALL), according to the October 15, 2003, issue of Blood, the official journal of the American Society of Hematology. Diagnosing a subtype of ALL can allow physicians to customize a treatment program based on a patient’s likelihood of responding to therapy.



Pediatric acute lymphoblastic leukemia has a number of subtypes, each with unique cellular and molecular characteristics. Since the subtype may also imply a less favorable prognosis, it is critical to diagnose each individual patient’s subtype so that therapy can be tailored to reduce the chance of a relapse. ALL patients currently have a 70 to 80 percent chance of surviving the disease, but the odds of survival decrease following a relapse.

ALL subtypes are used to assign patients to risk groups. Risk group assignment is an important element of cancer care because it allows physicians to avoid overtreating patients who are at low risk of relapse, while ensuring optimal treatment for patients with a high risk of relapse. Patients are currently classified into risk groups based on factors such as age and gender, white blood cell count, the presence or absence of leukemia in cerebral spinal fluid, and genetic characteristics of the leukemic cells. These risk features were identified from epidemiological studies and have resulted in excellent overall long-term survival rates, but gene expression profiling may provide an even more precise profile of a patient’s disease.


Researchers from St. Jude Children’s Research Hospital in Memphis, Tenn., utilized DNA microarray technology to study the pattern of genes expressed in a leukemic cell. DNA microarrays, also called gene chips, contain copies of known gene samples from the human body. Researchers used the Affymetrix HG-U133A and B microarrays to identify the set of human genes expressed in samples of cells taken from 132 pediatric ALL patients.

Computer-aided data analysis demonstrated that the pediatric ALL cases cluster into seven major subtypes, including the six known prognostic subtypes (BCR-ABL, E2A-PBX1, Hyperdiploid >50, MLL, T-ALL, and TEL-AML1) and an "other" category. The researchers were successful in using the expression profiles provided by the microarrays to accurately diagnose and subclassify pediatric ALL, and they discovered that changes in a cell’s expression profile vary markedly depending on the genetic lesions that underlie the initiation of the leukemic process.

"DNA expression profiling allows us to make extremely accurate diagnoses. If microarray technology can be implemented in a cost-effective manner, we may see a day when all leukemia patients undergo expression profiling and then have a unique treatment plan customized for them based on which genes are turned on and which are turned off in his or her leukemia cells," according to James R. Downing, M.D., of St. Jude Children’s Research Hospital, the senior author of the study.

Microarray technology also can reveal the mutated genes that cause cancer to develop, the first step in designing treatments that target the cause of the disease, not just the symptoms. If physicians can target and repair the damaged DNA, they may be able to stop cancer from progressing.

According to hematologist George Daley, M.D., Ph.D., of Children’s Hospital and Harvard Medical School, "Microarray studies of human leukemia have been at the forefront of efforts to exploit the human genome project to better diagnose and treat cancer, and have set the stage for similar insights into common solid tumors like breast and prostate cancer."


This work was supported in part by National Cancer Institute grants P01 CA71907-06 (JRD), CA-21765 (Cancer Center CORE grant to SJCRH), T32-CA70089, and by the American Lebanese and Syrian Associated Charities (ALSAC) of St. Jude Children’s Research Hospital.

To receive a copy of the study or to arrange an interview with James R. Downing, M.D., please contact Aislinn Raedy at 202-776-0544 or araedy@hematology.org.

The American Society of Hematology is the world’s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers twice per month, available in print and online at www.bloodjournal.org.

St. Jude Children’s Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fund-raising organization. For more information, please visit www.stjude.org.

Aislinn Raedy | EurekAlert!
Further information:
http://www.hematology.org/
http://www.stjude.org
http://www.bloodjournal.org

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>